Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization.
about
Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptorEstablishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleasesEvidence for limited genetic compartmentalization of HIV-1 between lung and bloodFunctional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody.Novel peptides based on HIV-1 gp120 sequence with homology to chemokines inhibit HIV infection in cell culture.Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization.Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.Fitness epistasis and constraints on adaptation in a human immunodeficiency virus type 1 protein regionDetection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing.Clustering of HIV-1 Subtypes Based on gp120 V3 Loop electrostatic propertiesHuman immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure.Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 bindingSensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kineticsIncreased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120.Genotypic prediction of tropism of highly diverse HIV-1 strains from CameroonSelected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v₃ signatures in the regulation of co-receptor usage.Interaction of the HIV-1 gp120 viral protein V3 loop with bacterial lipopolysaccharide: a pattern recognition inhibition.Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapyIsolation of CD4-independent primary human immunodeficiency virus type 1 isolates that are syncytium inducing and acutely cytopathic for CD8+ lymphocytes.Effect of lysine to arginine mutagenesis in the V3 loop of HIV-1 gp120 on viral entry efficiency and neutralization.Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy.Mutational pathways and genetic barriers to CXCR4-mediated entry by human immunodeficiency virus type 1.Screening and Functional Profiling of Small-Molecule HIV-1 Entry and Fusion Inhibitors.Antiviral activity of a Rac GEF inhibitor characterized with a sensitive HIV/SIV fusion assayIn silico Analysis of HIV-1 Env-gp120 Reveals Structural Bases for Viral Adaptation in Growth-Restrictive Cells.Characterization of a dual-tropic human immunodeficiency virus (HIV-1) strain derived from the prototypical X4 isolate HXBc2.Mapping of the CXCR4 binding site within variable region 3 of the feline immunodeficiency virus surface glycoprotein.Profile of HIV type 1 coreceptor tropism among Kenyan patients from 2009 to 2010Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma.Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptorHuman immunodeficiency virus type 1 genomic RNA sequences in the female genital tract and blood: compartmentalization and intrapatient recombination.The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle.Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein.Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.In vivo CXCR4 expression, lymphoid cell phenotype, and feline immunodeficiency virus infection.The C-terminal proline-rich tail of human immunodeficiency virus type 2 Vpx is necessary for nuclear localization of the viral preintegration complex in nondividing cells.
P2860
Q28345395-D7685F29-EF32-439A-8FD0-ABF28AB05143Q28346124-CC07FE95-F443-45C4-B288-BCABCE94943BQ29615069-080B9402-D804-4CDC-8D78-79F0BA60DA73Q33504173-01F27C98-9939-4537-99CA-4C981279DAE4Q33780450-65CBB3A6-2D97-4417-99D9-6252E7B11267Q33802789-31293BD5-A21F-41BB-B367-038D79E978E8Q33841969-4CE90068-5A25-4F6F-994D-9B1138756F35Q33842152-36F93C8F-BFEE-4D06-A3E2-0CCADD6E42E9Q33853183-70985A5D-3468-4B0A-8254-50C48E09D8E2Q33951977-3F43AD05-C582-40D8-9A9D-82BF70FE9DBBQ34153074-1F253822-FCF7-43CC-90F8-C8405AF7E184Q34301803-D2774EE1-BB23-4462-86CE-9BE0CC000BD5Q34342200-D01BD04B-CFCF-4C6F-BF6A-D7D358FD3BC3Q34349528-3D33F984-342B-4079-A84A-D29855550224Q34415921-7A16FF44-0C05-48AF-9E39-466FB91954B9Q34464860-D15C7094-4432-4245-9C27-2D0D3A9EBD70Q34473354-7B68F7BE-091B-48C5-B607-4BC908519EC8Q35052934-31B8236C-CE78-44D3-9706-BF9C3081372DQ35111062-AC434DAD-12D3-4BA3-961E-40936A0AC565Q35264750-B298A1CC-6B5D-4B8D-AA4D-7964EA1E731DQ35543127-83BD2ADA-6F21-4C4E-BAF4-8DA70CC36A7EQ35580330-8E92A11A-4A87-436B-9FDB-7C825CEA33BEQ36011358-DB8BDFDF-B9E8-434A-BD65-44FA7C99140DQ36191170-62A04F03-E116-4E53-A359-73C53A47A479Q36316050-BA69398F-646F-4FD1-9D23-7E78E56B2819Q36326038-8D3B79D7-6A34-432F-B9D2-15A81656210BQ36558933-B1699690-19E7-423D-B496-6B5624E4AD4CQ36674792-FBC22D50-F122-4DE9-B49E-45CB05E2A46BQ36898649-FEEFFFDE-449A-4C21-BFEF-10C1D9F61B6CQ37025683-10A4418A-B560-419A-9E9B-E8C2DAA1AB4AQ37051645-5C459708-AD56-4FAE-9006-8F17945D1A0CQ37452124-ED23926A-F161-442A-BDA2-5A9F36B6055BQ37525642-C95AAC20-54A6-4E83-A723-74A6DA7A4CEBQ37730009-0B45A355-CC8A-4668-8D1C-42AA67F2AC4FQ37746512-1B392887-306E-4AD2-842F-BE1D1D9C1D06Q37747105-2AADD744-1D50-430B-ABA7-16A332C29DD0Q38610610-B82BE90A-C68E-4B34-9B79-722F6DC50773Q38968180-9F466BF3-F336-4A2D-8ED1-0EDD9F0577CFQ39038623-4470416D-200F-41E9-B35B-C187EDECBF7BQ39591808-63479487-61D4-455D-86E4-148182707382
P2860
Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Analysis of the critical domai ...... involved in CCR5 utilization.
@ast
Analysis of the critical domai ...... involved in CCR5 utilization.
@en
type
label
Analysis of the critical domai ...... involved in CCR5 utilization.
@ast
Analysis of the critical domai ...... involved in CCR5 utilization.
@en
prefLabel
Analysis of the critical domai ...... involved in CCR5 utilization.
@ast
Analysis of the critical domai ...... involved in CCR5 utilization.
@en
P2093
P2860
P1433
P1476
Analysis of the critical domai ...... involved in CCR5 utilization.
@en
P2093
N Vander Heyden
P2860
P304
P577
1999-10-01T00:00:00Z